Purpose To investigate the dose linearity of celecoxib (CEL) pharmacokinetics from various
non-lipid and lipid-based formulations; to probe the mechanisms of CEL absorption from a …

This study is the first to demonstrate in canines the ability of silica-lipid hybrid (SLH)
microparticles to enhance the bioavailability and efficacy of a poorly water-soluble drug after …

We investigate the role of hydrophilic fumed silica in controlling the digestion kinetics of lipid
emulsions, hence further exploring the mechanisms behind the improved oral absorption of …

The present study investigated the oral bioavailability of celecoxib when incorporated into
solid lipid nanoparticles either dissolved or suspended. In vitro drug release in different …

Celecoxib (CXB) is a Biopharmaceutical Classification System (BCS) Class II molecule with
high permeability that is practically insoluble in water. Because of the poor water solubility …

A silica-lipid hybrid (SLH) microcapsule system for oral delivery of poorly water-soluble
drugs is reported for the first time. For the model drug celecoxib (CEL), SLH microcapsules …

Celecoxib (CXB) is a Biopharmaceutical Classification System class II drug in which its oral
bioavailability is limited by poor aqueous solubility. Although a range of formulations aiming …

Phospholipids are amphiphilic lipids with versatile properties making them promising
excipients for enabling formulations for oral drug delivery. Unfortunately, systematic studies …

Celecoxib (CLX) is a selective cyclooxygenase-2 (COX-2) inhibitor; however, the application
of CLX is compromised due to its poor aqueous solubility and low oral bioavailability. This …

We investigate the physicochemical characteristics of celecoxib (CEL) entrapped within
particles of an oxidized porous silicon matrix (pSiox); determine the oral dose response of …